We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Due 2025, the notes carry a rate of 5.5%. The US-based pharmaceutical company plans to use the funds to repurchase the principal amount of outstanding notes.